that triggers dopamine loss.
“A lot of work still needs to happen, but this molecule has the potential to be a pre-cursor to a drug. Today there are only medicines to treat the symptoms of Parkinson’s we hope to develop a drug that can return people to good health even before symptoms develop,” says Professor Jody Mason, who led the analysis from the Department of Biology and Biochemistry at Bath.
Potential Drug for Parkinson’s Disease
There have been a number of efforts to goal and ‘detoxify’ αS-induced neurodegeneration and doubtlessly discover a treatment for PD.
Recently, the research crew has discovered {that a} new model of a peptide 4554W 4654W(N6A) has been confirmed to considerably cut back the αS misfolding, aggregation, and toxicity. However, additional experiments are required to extract the advantages of the molecule as a whole treatment for PD.
“The effectiveness of the 4654W(N6A) peptide on alpha synuclein aggregation and cell survival in cultures is very exciting, as it highlights that we now know where to target on the alpha synuclein protein to supress its toxicity. Not only will this research lead to the development of new treatments to prevent the disease, but it is also uncovering fundamental mechanisms of the disease itself, furthering our understanding of why the protein misfolds in the first place,” says Dr. Richard Meade, the lead creator of the research.
Source: Medindia
